Close Menu

Immunoassays

News on immunoassay systems and applications.

The extended deal covers multiple blood cancer and solid tumor indications and will leverage several HalioDx technologies and approaches.

The cancer immunotherapy regimen and companion diagnostic test will be available in Europe for patients with triple-negative breast cancer who express PD-L1. 

The two companies will work together to bring the point-of-care pretreatment diagnostic based on the XDX-01 biomarker to market in 2020.

The VISTA T cell-inhibiting protein found on macrophage immune cells may contribute to poor pancreatic ductal adenocarcinoma outcomes, new research finds.

Sebia and Janssen Biotech collaborated on the development of the test, which is for assessing patients treated with Darzalex.